L3VLUP
ProSign in

STE · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

STEVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • STE
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterSTEVRTX
Q3 20209 holders, $1.8bn31 holders, $21.9bn
Q4 202011 holders, $1.8bn30 holders, $18.4bn
Q1 20219 holders, $1.8bn31 holders, $15.4bn
Q2 202113 holders, $1.9bn30 holders, $12.7bn
Q3 202111 holders, $2.0bn35 holders, $10.1bn
Q4 20219 holders, $2.9bn28 holders, $12.4bn
Q1 202210 holders, $3.3bn23 holders, $16.1bn
Q2 202210 holders, $2.7bn25 holders, $18.1bn
Q3 202211 holders, $2.0bn22 holders, $18.4bn
Q4 20229 holders, $2.2bn28 holders, $18.4bn
Q1 202310 holders, $2.5bn26 holders, $21.4bn
Q2 202310 holders, $2.8bn27 holders, $24.7bn
Q3 202312 holders, $2.6bn33 holders, $24.3bn
Q4 20238 holders, $2.5bn32 holders, $28.6bn
Q1 20248 holders, $2.6bn31 holders, $29.8bn
Q2 20247 holders, $2.2bn29 holders, $33.4bn
Q3 20247 holders, $2.4bn27 holders, $33.5bn
Q4 20247 holders, $1.4bn26 holders, $28.5bn
Q1 20257 holders, $1.7bn21 holders, $35.4bn
Q2 202512 holders, $2.2bn21 holders, $32.3bn
Q3 20259 holders, $2.4bn22 holders, $25.9bn
Q4 202512 holders, $3.2bn26 holders, $31.8bn
Q1 202613 holders, $3.4bn25 holders, $31.8bn
Q2 202617 holders, $3.6bn26 holders, $34.6bn
STE

Steris PLC

Holders
12
Reported value
$2.2bn
Buyers
7
Sellers
4

Breadth +3 among 95 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
VRTX

Vertex Pharmaceuticals Inc

Holders
21
Reported value
$32.3bn
Buyers
11
Sellers
11

Breadth 0 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2025

Among the 28 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only STE (7)

Arrowstreet Capital LP, ExodusPoint Capital Management LP, GAMCO Investors Inc, Holocene Advisors LP, Point72 Asset Management LP, Two Sigma Investments LP, Winton Group Ltd

Only VRTX (16)

AllianceBernstein LP, ARK Investment Management LLC, Artisan Partners LP, Baillie Gifford & Co, Capital Research Global Investors, Capital World Investors, Fidelity (FMR LLC), Hudson Bay Capital Management LP, Man Group PLC, Marshall Wace LLP, Neuberger Berman Group LLC, Renaissance Technologies LLC, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Wellington Management Group LLP, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →